Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
Tutorial
This icon indicates there is a poll question. Click it when you see it to interact with your peers.
touchPANEL DISCUSSION
A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity.
Close
Expanding HER2 horizons: Implications for NSCLC and beyond
Learning Objectives
After watching this activity, participants should be better able to:
- Evaluate the clinical implications for tissue-agnostic HER2-targeted treatments for patients with advanced cancer
- Discuss the latest data for HER2 targeting therapies in patients with advanced NSCLC and HER2 alterations
- Outline best practices and guidelines for biomarker testing to establish HER2 status in patients with advanced NSCLC
Overview
In this activity, two medical oncologists and a pathologist discuss key considerations on tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, pulmonologists and pathologists involved in the management of patients with solid tumours, including NSCLC.
USF Accreditation
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Lyudmila Bazhenova discloses: Advisory board or panel fees from Abbvie, Anheart, AstraZeneca, Bayer, Bioatla, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, Janssen, Merck, Neuvogen, Novocure, Pfizer, Regeneron, Sanofi, Summit and Teligene (All Relationships Terminated). Consulting fees from Daichi and Pfizer (All Relationships Terminated).
Dr Razelle Kurzrock discloses: Grant/research support from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance. Advisory board/panel, consultant and speaker’s bureau fees from Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, CureMetrix, Daiichi, Datar Cancer Genetics, Eisai, EOM Pharmaceuticals, Iylon, LabCorp, Lanuaria, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Regeneron, Roche, Turning Point Therapeutics, Volastra and X-Biotech. Support (royalties, patent, etc.) Dr Kurzrock is the co-founder and serves on the board of CureMatch.
Dr Ignacio Wistuba discloses: Advisory board or panel fees from Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst Therapeutics, Daiichi Sankyo, Flame, Genentech/Roche, Gl Therapeutics, Guardant Health, Janssen, Johnson & Johnson, Merck, Merus, Novartis, Oncocyte, Pfizer, Regeneron and Sanofi. Grants/research support from 4D, Adaptimmune, Adaptive, Akoya, Amgen, Bayer, Bristol Myers Squibb, EMD Serono, Genentech, Iovance, Johnson & Johnson, Karus, Medimmune, Merck, Novartis, Pfizer and Takeda. Speaker’s bureau fees from AstraZeneca, Genentech/Roche, Medscape, Merus, Merck, Pfizer and Platform Health.
Content reviewer
Danielle Walker, DNP, APRN, AGNP-C has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75Â Category 1Â credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 25 September 2024. Date credits expire: 25 September 2025.
If you have any questions regarding credit, please contact cpdsupport@usf.edu
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.
Claim CreditYou may also be interested in...
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out